Connect with us

Politics

Hawaii Lawmakers Introduce Plan To Study Psychedelic Mushrooms With Goal Of Legalizing Access

Published

on

A pair of Hawaii lawmakers is pushing to explore the therapeutic potential of psychedelic mushrooms, introducing legislation that could one day make psilocybin-based products available to medical patients in the state.

The package of resolutions, introduced last week by Sen. Les Ihara Jr. and Rep. Chris Lee, both Democrats, asks the state Department of Health to convene a “medicinal psilocybin working group” that would examine available evidence around the use of psychedelic mushrooms and eventually “develop a long-term strategic plan to ensure the availability of medicinal psilocybin or psilocybin-based products that are safe, accessible, and affordable for eligible adult patients.”

The proposal comes as a number of other jurisdictions around the U.S. explore relaxing laws around psychedelics, such as by expanding opportunities for therapeutic use or decriminalizing simple possession. In Hawaii, possession of psilocybin mushrooms is currently illegal under both state and federal law.

The new Hawaii legislation frames reform in purely medical terms, arguing that the state “has a shortage of mental health professionals, and should actively consider novel, innovative, and safe solutions to treat its citizens.”

“Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions,” the measures say, “including addiction, depression, anxiety disorders, and end-of-life psychological distress.”

Literature suggesting that psilocybin may effectively treat a wide range of mental health and addiction disorders has been piling up in recent years, although most preliminary studies have led to calls for further research into how it and other psychedelics are used.

A research center at Johns Hopkins Medicine launched last year to study the therapeutic potential of psilocybin and other psychedelic substances on various conditions, including post-traumatic stress disorder, Alzheimer’s disease, opioid use disorder, treatment-resistant depression, eating disorders and others.

The Hawaii legislation notes that the Food and Drug Administration “has determined that preliminary clinical evidence indicates that psilocybin may demonstrate substantial improvement over available therapies for major depressive disorder and severe treatment-resistant depression.”

The federal agency in recent years has granted “breakthrough therapy” designations to two specific psilocybin-based clinical treatments, one that uses the substance to treat major depressive disorder and another that uses it as a therapy for severe treatment-resistant depression.

The federal Controlled Substances Act classifies psilocybin and another compound found in psychedelic mushrooms, psilocin, as Schedule I controlled substances. Recent studies challenge that status, which is supposed to be reserved for drugs that have no accepted medical use and may not be safely used even under clinical supervision.

Under the Hawaii plan, the state would assemble a working group consisting of a mixture of state officials, medical professionals, drug policy advocates and other experts. That group would examine available research and submit a preliminary findings report to the legislature before the start of the 2021 legislative session.

A year later, before the start of the 2022 legislative session, the group would file a final report with “findings and recommendations, including any proposed legislation” to lawmakers, which could set up a push to legalize psilocybin-based products.

The resolutions to study psilocybin—SR 196, SCR 241, HR 176 and HCR 195—were introduced in their respective chambers last week.

Meanwhile, other jurisdictions around the country are weighing psychedelic reform efforts of their own. In Vermont, lawmakers in January filed a bill that would decriminalize three psychedelic substances, including psilocybin.

In Oregon, activists are working to put therapeutic psilocybin legalization on the ballot. Meanwhile, reform advocates in the state say they’ve collected enough signatures to put a separate measure before voters that would decriminalize small-scale possession of all drugs and greatly expand access to treatment.

Activists in Oakland, which last year became the first city to decriminalize a wide range of psychedelics, are now exploring the possibility of allowing for the lawful sale of the entheogenic substances in a limited, community-driven system. Statewide in California, reform advocates are collecting signatures for an initiative to legalize psilocybin.

And in Washington, D.C., activists who are working to qualify a local ballot measure to decriminalize psychedelics recently asked district officials for permission to continue its signature-gathering over the internet due to coronavirus concerns.

Hawaii lawmakers are also currently considering a bill that would remove the possibility of felony charges for low-level drug offenses—a proposal that cleared the Senate last week. Critics complain that people caught with drugs for personal use could still face incarceration under the proposal.

Medical marijuana became legal in Hawaii in 2000, but legal dispensaries didn’t open until 2017. As for non-medical use, a measure that decriminalized small-scale cannabis possession in the state took effect in January.

New Vermont Bill Would Decriminalize Psychedelics And Kratom

Photo courtesy of Wikimedia/Workman

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Ben Adlin is a Seattle-based writer and editor. He has covered cannabis as a journalist since 2011, most recently as a senior news editor for Leafly.

Politics

Senator Files New Bill To Federally Legalize Marijuana And Regulate It Like Tobacco

Published

on

A Democratic senator filed a new bill to federally legalize marijuana on Thursday, creating yet another potential avenue through which Congress could enact the policy change.

This piece of legislation, sponsored by Sen. Tina Smith (D-MN), would remove cannabis from the Controlled Substances Act and direct several federal agencies to develop regulations for the plant.

Titled the “Substance Regulation and Safety Act,” the bill would deschedule cannabis, require the U.S. Department of Health and Human Services (HHS) to develop rules that treat marijuana the same as tobacco, create a national research institute to evaluate the risks and benefits of cannabis, require the U.S. Department of Agriculture to impose quality control standards and mandate that the Department of Transportation study methods for detecting THC-impaired driving.

The descheduling provisions “are retroactive and shall apply to any offense committed, case pending, or conviction entered, and, in the case of a juvenile, any offense committed, case pending, or adjudication of juvenile delinquency entered, before, on, or after the date of the enactment of this Act,” the text of the bill states.

HHS would have to come up with a “national strategy to prevent youth use and abuse of cannabis, with specific attention to youth vaping of cannabis products.” Further, text of the legislation states that the department would be required to “regulate cannabis products in the same manner, and to the same extent,” as it does with tobacco.

That includes “applying all labeling and advertising requirements that apply to tobacco products under such Act to cannabis products.”

U.S. Customs and Border Protection would be tasked with working with other agencies to develop policies on allowing marijuana imports and exports.

The legislation further contains racial justice provisions. For example, HHS would have to consult with “consult with civil rights stakeholders” to determine “whether cannabis abuse prevention strategies and policies are likely to have racially disparate impacts” within 100 days of the bill’s enactment.

The Department of Transportation would similarly have to determine whether its impaired driving prevention policy “is likely to contribute to racially disparate impacts in the enforcement of traffic safety laws.”

Agencies charged with establishing these regulations would have one year following the bill’s enactment to finalize those rules.

A federal age requirement for marijuana sales would be set at 21 under the measure.

The short title of the bill as published on Congress’s website states that it would “decriminalize and reschedule cannabis.” However, the text of the legislation as introduced that was shared with Marijuana Moment says it would go beyond rescheduling by removing marijuana from the CSA entirely, a process known as descheduling. Representatives from Smith’s office did not immediately respond to a request for clarification.

This is the latest legalization bill to be introduced this Congress. In some ways, it appears to be a more modest reform compared to other pieces of legislation that reform advocates are backing such as the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, which includes provisions beyond rescheduling to reinvest in communities most impacted by the war on drugs.

Sources recently told Marijuana Moment there are plans in motion to get a House floor vote on that bill in September, though it’s prospects in the Republican-controlled Senate are more dubious. It’s possible that this bill from Smith would be more palatable to GOP members given its more narrow focus.

“It’s terrific to see Senator Smith engage so substantively in the cannabis policy reform debate,” Justin Strekal, political director of NORML, told Marijuana Moment. “We at NORML look forward to propelling many aspects of the new legislation into the broader conversation on the future of federal regulations in regards to a post-prohibition America.”

The introduction of this legislation comes one day after the House approved a spending bill amendment that would protect all state, territory and tribal cannabis programs from federal intervention.

While Smith has only been in Congress since 2018, after she replaced Sen. Al Franken (D-MN) following his resignation, she has signed onto various pieces of cannabis reform legislation as a cosponsor, and she’s made several comments in favor of reform.

For example, the senator attached her name to bills to protect banks that service state-legal marijuana businesses from being penalized from federal regulators and to legalize industrial hemp. She also cosponsored a resolution condemning “state-sanctioned extrajudicial killings” over drug crimes in the Philippines.

Smith also recently remarked racial disparities in drug enforcement in a Senate floor speech.

This bill is being introduced as Minnesota lawmakers push for state-level legalization, with a top legislator unveiling a comprehensive plan for legalizing cannabis for all adults 21 and older in May.

It also comes shortly after the Democratic National Committee rejected an amendment to adopt legalization as a 2020 party plank, with members opting instead to embrace more modest reforms. Advocates suspend that there may have been pressure for the panel not to formally embrace a policy change that is opposed to by presumptive Democratic presidential nominee Joe Biden.

Read the new Senate marijuana legalization below: 

Substance Regulation and Sa… by Marijuana Moment on Scribd

Photo courtesy of WeedPornDaily.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Louisiana Law Allowing Medical Marijuana For Any Debilitating Condition To Take Effect

Published

on

A new Louisiana law significantly expanding the state’s medical marijuana program officially takes effect on Saturday.

This comes two months after the legislature approved the bill and Gov. John Bel Edwards (D) signed it. The legislation will allow physicians to recommend medical cannabis to patients for any debilitating condition that they deem fit instead of from the limited list of maladies that’s used under current law.

Other new laws coming into force this weekend include ones to set hemp and CBD regulations, shield financial institutions that service marijuana businesses from being penalized by state regulators and provide legal protections for doctors who recommend medical cannabis and medical facilities that have marijuana patients in their care.

The medical marijuana expansion bill as introduced by its sponsor, Rep. Larry Bagley (R), initially only would have added traumatic brain injuries and concussions but was amended in committee to include several other conditions as well as language stipulating that cannabis can be recommended for any malady that a physician “considers debilitating to an individual patient.”

“I’m excited. I’m expecting it to be a pretty big day,” Bagley told Marijuana Moment in a phone interview on Thursday. “All the people out here tell me all the wonderful stories about how they were in terrible pain and then they took it and then they’ve gotten away from the pain.”

The lawmaker is particularly hopeful that providing this expanded access will help curb the opioid epidemic by providing patients with a safer alternative to prescription painkillers.

“The medical marijuana is not [like opioids] because not not addictive. No one’s ever died from it,” he said.

“I’m hopeful I think this is gonna be a big day. I’m really expecting this to be a game changer for Louisiana, for the state, for the pharmacies that are doing this,” he said. “I think it’s going to be a big moneymaker for state. At least I hope it is. And I think that everybody’s going to be really happy about it, but time will tell.”

Bagley had also introduced a House-passed bill to allow delivery services, but he voluntarily withdrew it from Senate committee consideration, telling Marijuana Moment at the time that he felt the debilitating condition bill would already allow cannabis products to be delivered to patients like other traditional pharmaceuticals.

The delivery bill would have required a government regulatory body to develop “procedures and regulations relative to delivery of dispensed marijuana to patients by designated employees or agents of the pharmacy.”

It remains to be seen if regulators will agree with Bagley’s interpretation, as doctors are still prohibited from “prescribing” cannabis, and marijuana products are not dispensed through traditional pharmacies. But regulators did move to temporarily authorize delivery services during the coronavirus pandemic, so it’s possible they will be amenable to extending the allowance on a permanent basis.

State lawmakers also passed a resolution in June to create “a task force to study and make recommendations relative to the cannabis industry projected workforce demands.” Text of the legislation, which does not require gubernatorial action, states that “there is a need to study the workforce demands and the skills necessary to supply the cannabis industry with a capable and compete workforce, including physicians, nurse practitioners, nurses, and other healthcare practitioners.”

Nancy Pelosi Says Marijuana Is A ‘Therapy That Has Proven Successful’ Amid Coronavirus Bill Debate

Photo courtesy of WeedPornDaily.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Nancy Pelosi Says Marijuana Is A ‘Therapy That Has Proven Successful’ Amid Coronavirus Bill Debate

Published

on

House Speaker Nancy Pelosi (D-CA) on Friday defended the decision to include marijuana banking protections in Democrats’ latest coronavirus relief bill.

The speaker was asked about various provisions of the legislation that Republicans had criticized as not germane to the health crisis, with a reporter citing the cannabis component in particular. Pelosi took issue with the suggestion and said there is a role for marijuana reform amid the pandemic.

“I don’t agree with you that cannabis is not related to this,” the top House Democrat said. “This is a therapy that has proven successful.”

It’s not clear whether the speaker was suggesting that marijuana has medical value for a coronavirus infection specifically or was more broadly referencing the plant’s therapeutic potential. The Food and Drug Administration has made clear that there’s currently no solid evidence that cannabinoids can treat COVID-19 and it’s warned companies that make that claim.

Several lawmakers have argued that the Secure and Fair Enforcement (SAFE) Banking Act is relevant to the health crisis for a different reason, as protecting financial institutions that service cannabis businesses would mean fewer cash exchanges at dispensaries, thus minimizing the spread of the virus.

Marijuana Moment previously exclusively reported that Pelosi—who said in 2018 that doctors should prescribe medical cannabis and yoga more often instead of prescription opioids—supported attaching the banking language to the House’s coronavirus package prior to the legislation’s introduction.

That said, Senate leadership unveiled their latest round of coronavirus relief legislation on Monday, and it does not include the SAFE Banking Act provisions. It remains to be seen whether bicameral negotiators will be able to get it in the final bill sent to the president’s desk.

Rep. Ed Perlmutter (D-CO) said in May that he felt there was a 50-50 chance the Senate would adopt it as part of their COVID-19 bill.

On Friday, House Minority Leader Kevin McCarthy (R-CA) took to Twitter to slam Pelosi’s latest cannabis comments.

“Hey Nancy, let’s focus on the pandemic. Not pot,” he said.

The Senate Republican Communications Center also chimed in.

“House Democrats are continuing to try and push unrelated COVID-19 wish-list items. All of them should be taken out,” the group tweeted.

Meanwhile, the standalone SAFE Banking Act has continued to sit in the Senate Banking Committee without action in the months since the House initially approved it.

Earlier this month, a bipartisan coalition of state treasurers sent a letter to congressional leaders, asking that they include marijuana banking protections in the next piece of coronavirus relief legislation.

In May, a bipartisan coalition of 34 state attorneys general similarly wrote to Congress to urge the passage of COVD-19 legislation containing cannabis banking provisions.

Pelosi’s latest comments come one day after the House approved an amendment to protect state, territory and tribal marijuana laws from federal interference.

House Votes To Protect State Marijuana Laws From Federal Interference

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!